Brent Standridge
2018
In 2018, Brent Standridge earned a total compensation of $799.8K as Chief Operating Officer at Aratana Therapeutics, a 30% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $92,100 |
|---|---|
| Option Awards | $189,953 |
| Salary | $315,000 |
| Stock Awards | $191,751 |
| Other | $11,000 |
| Total | $799,804 |
Standridge received $315K in salary, accounting for 39% of the total pay in 2018.
Standridge also received $92.1K in non-equity incentive plan, $190K in option awards, $191.8K in stock awards and $11K in other compensation.
Rankings
In 2018, Brent Standridge's compensation ranked 10,201st out of 14,244 executives tracked by ExecPay. In other words, Standridge earned more than 28.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,201 out of 14,244 | 28th |
Division Manufacturing | 4,114 out of 5,765 | 29th |
Major group Chemicals And Allied Products | 1,546 out of 2,128 | 27th |
Industry group Drugs | 1,307 out of 1,817 | 28th |
Industry Pharmaceutical Preparations | 1,006 out of 1,391 | 28th |
Source: SEC filing on April 19, 2019.
Standridge's colleagues
We found two more compensation records of executives who worked with Brent Standridge at Aratana Therapeutics in 2018.